Incyte Corp Ltd (INCY): Drugs' Featured Underachiever Of The Day

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Incyte ( INCY) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.5%. By the end of trading, Incyte fell 23 cents (-1%) to $22.77 on average volume. Throughout the day, 1.6 million shares of Incyte exchanged hands as compared to its average daily volume of 1.8 million shares. The stock ranged in price between $22.67-$23.45 after having opened the day at $23.06 as compared to the previous trading day's close of $23. Other companies within the Drugs industry that declined today were: Star Scientific ( STSI), down 10.7%, Affymax ( AFFY), down 8.1%, Inovio Pharmaceuticals ( INO), down 8%, and Tranzyme ( TZYM), down 6.9%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. Incyte has a market cap of $3.13 billion and is part of the health care sector. Shares are up 38.5% year to date as of the close of trading on Monday. Currently there are 11 analysts that rate Incyte a buy, one analyst rates it a sell, and two rate it a hold.

TheStreet Ratings rates Incyte as a sell. Among the areas we feel are negative, one of the most important has been poor profit margins.

On the positive front, Optimer Pharmaceuticals ( OPTR), up 19.2%, Obagi Medical Products ( OMPI), up 16.1%, Idera Pharmaceuticals ( IDRA), up 11.4%, and Astex Pharmaceuticals ( ASTX), up 10.5%, were all gainers within the drugs industry with Merck ( MRK) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Apache, Incyte, Prudential, ON Semiconductor: 'Mad Money' Lightning Round

Apache, Incyte, Prudential, ON Semiconductor: 'Mad Money' Lightning Round

Playing Defense and Offense: Cramer's 'Mad Money' Recap (Tuesday 11/7/17)

Playing Defense and Offense: Cramer's 'Mad Money' Recap (Tuesday 11/7/17)

Who Benefits From Tax Reform?

Who Benefits From Tax Reform?

Geron Shares Rise on Fast Track Designation -- Biotech Movers

Geron Shares Rise on Fast Track Designation -- Biotech Movers